Stabilized hydroxylamine solutions

Abstract

A stabilized hydroxylamine solution is disclosed. The stabilized solution comprises a selected stabilizer, which can be added during manufacture and/or storage of the hydroxylamine solution.

Description

BACKGROUND OF THE INVENTION

[0001] 1. Field of the Invention

[0002] This invention relates to a stabilized hydroxylamine solution, and more particularly, to a hydroxylamine solution, which comprises a selected stabilizer.

[0003] 2. Description of the Related Art

[0004] Hydroxylamine, especially in the form of its salts with sulfuric acid, hydrochloric acid and others, is an important intermediate for the chemical industry, and is widely employed in chemical syntheses. It is frequently necessary to employ hydroxylamine in the form of a solution of the free base, which is generally liberated from a hydroxylammonium salt such as, for example, hydroxylammonium sulfate or hydroxylammonium chloride, by the action of an appropriate base, such as ammonia, sodium hydroxide solution or an alcoholate. Neutral and alkaline hdyroxylamine solutions are unstable and decompose to form ammonia, nitrogen, oxides of nitrogen and water, so that their transportation or storage is highly problematic. The rate of decomposition increases with rising temperature, rising hydroxylamine concentration, rising pH and rising concentration of catalytically active impurities.

[0005] In Order to avoid the decomposition of the hydroxylamine, a stabilizer is added to the solutions. Numerous stabilizers for hydroxylamine are already known. Proposals which have been made are: thioglycolic acid (JP-A-58069843), glycerol monethers and ethylene oxide adducts thereof (DE-A-29 19 554), hydroxyanthraquinones (DE-A-33 43 600), hydroxyquinolines (DE-A-33 45 734), polyhydroxyhexano-1,4-lactone (DE-A-33 45 733), anthocyanins (DE-A-33 47 260), hydroxyquinaldines, flavones, benzonitrile, N-phenyl-N hydroxythiourea (DE-A-36 01 803), flavans (DE-A-33 43 599), thiosulfates, mercaptobenzothiazoles, mercaptoalkanols, mercaptothiazolines, thiuram disulfides, thioureas (EP-A-516 933), the tetrasodium salt of ethylenediaminetetraacetic acid, the trisodium salt of N-hydroxyethylenediaminetriacetic acid, polyvinylpyrrolidone or poly-N-vinyl-5-ethyl-2-oxazolidinone (U.S. Pat. No. 3,145,082), amide oximes (U.S. Pat. No. 3,480,391), hydroxamic acids (U.S. Pat. No. 3,480,391), hydroxyureas (U.S. Pat. No. 3,544,270), dipyridyl compounds (JP-A-58069842), aminoquinolines (JP-A-58069844), phenanthrolines (JP A-58069841), and polyhydroxyphenols (JP-A-4878099).

[0006] However, none of the stabilizers proposed to date has been able to provide hydroxylamine solutions with sufficient stabilization to prevent excessive decomposition of the hydroxylamine to occur, especially during storage.

[0007] What is desired and needed is a better means for stabilizing a hydroxylamine solution.

DETAILED DESCRIPTION OF THE INVENTION

[0008] This Invention relates to a stable hydroxylamine solution, and more particularly, to such a solution, which comprises a selected stabilizer.

[0009] Hydroxylamine is prepared commercially by the Raschig process or variations thereof, in which ammonium or sodium nitrite is reacted in aqueous solution with ammonium or sodium bi-sulfite and sulfur dioxide. The resulting disulfonate salts are subsequently hydrolyzed to a solution containing essentially hydroxylammonium sulfate, sulfuric acid, ammonium sulfate and/or sodium sulfate plus minor amounts of the corresponding nitrate. This solution can be used, after neutralization with a base, as a source of hydroxylamine or pure hydroxylammonium salts from the mixture.

[0010] A suitable selected stabilizer is selected. A suitable selected stabilizer is a compound which complexes or chelates metals, such as for example, Ca, Fe, Zn, Al, Cu, Ni, etc., which catalyze the decomposition of an aqueous hydroxylamine solution during its manufacture, storage and transportation. Such a stabilizer includes (a) diethylenetriaminepentaacetic acid (“DPTA”), (b) triethylenetetraminehexaacetic acid (“TTHA”), (c) ethylene-bis(oxyethylenentirilo)tetraacetic acid (“EGTA”), (d) 1,4,8,11-tetraazacyclotetradecane-1,4,8-11-tetraacetic acid, (e) 4,8-dihydroxyquinoline-2-carboxylic acid, (f) 4,5-dihydroxy-1,3-benzene-disulfonic acid, (g) 4,7-dihydroxy-1,10-phenanthroline, (h) 2-mercaptonicotinic acid, (i) bis[N,N′-bis(carboxymethyl)aminomethyl]fluorescein [fluorexon], (j) N,N-bis(2-carboxyethyl)-N,N′ethylenediglycine trihydrate, (k) Cystine, (1) 2,3-dihydroxybenzoic acid, (m) Thiosalicyclic acid, (n) a mixture of the any of the foregoing compounds and (n) and the salts of any of the foregoing compounds. Particularly preferred salts of the selected stabilizers include amine salts, e.g. triethylamine, triethanolamine; hydroxyamines; acid addition salts with inorganic acids, e.g. HF, HCl, HBr, H2SO4, H3PO4, etc., if basic functions are present.

[0011] The selected stabilizer is added or combined either with the reactants during the process for manufacturing the hydroxylamine solution, or during the storage of a basic or neutralized aqueous solution of such manufactured hydroxylamine.

[0012] The selected stabilizer is added to the reactants, e.g. Raschig process reactants, or to a neutral or basic aqueous hydroxylamine solution, e.g. in excess of 50-weight percent hydroxylamine solution, in an amount sufficient to stabilize the hydroxylamine solution. By “stabilize” is meant that the hydroxylamine concentration in the neutral or basic solution does not decompose or decrease by 2.0 weight percentage in a time period of 24 hours at a temperature of 25° C. Typically, the final concentration of the added selected stabilizer is present in the resultant neutral or basic hydroxylamine solution in an amount ranging from about 0.005 percent to about 0.1 percent by weight to the total weight of the resultant solution. In this regard, the concentration of hydroxylamine is in general 1-100% by weight, in particular 1-70% by weight, based an the overall weight of the resultant solution.

[0013] It is to be pointed out that the selected-stabilizer can be used as a single selected stabilizer or as a mixture of at least two selected stabilizers. Additionally, the selected stabilizer or stabilizers (mixture) can be combined with other well known stabilizer, such as, thioglycolic acid, glycerol monethers and ethylene oxide adducts thereof, hydroxylanthroquinones, hydroxyquinolines, polyhydroxyhexano-1,4-lactone, anthocyanins, hydroxyquinaldines, flavones, benzonitrile, N-phenyl-N-hydroxythiourea, flavans, thiosulfates, mercaptobenzothiazoles, mercaptothiazolines, thiuram disulfides, thioureas, the tetrasodium salt of ethylenediaminetetraacetic acid, the trisodium salt of N-hydroxyethylethylenediaminetriacetic acid, polyvinylpyrrolidone or poly-N-vinyl-5-ethyl-2-oxazolidinone, amide oximes, hydroxamic-acids, hydroxyureas, dipyridyl compounds, aminoquinolines, phenanthrolines, and polyhydroxyphenols. In this regard, reference is also made to U.S. Pat. No. 5,783,161, which reveals other stabilizers.

Stabilizer for H-Base
Weight Loss Screening Test
Hydroxylamine (HA) and Ammonia Determination after
Weight Loss Screening Test
			% HA	% ammonia
	Wt	% wt	remaining after	formed during
1997 stabilized 56% HA + Fe(III) + Candidate	loss g	loss	screening test	screening test	comment
Diethylenetriaminepentaacetic acid	0	0	56	0
Triethylenetetraminehexaacetic acid	0	0	55	0
(TTHA)
Ethylenebis(oxyethylenenitrilo)tetra-	0	0	52	0
acetic acid (EGTA)
1,4,8,11-tetraazacyclotetradecane-	0	0	54	0
1,4,8,11-tetraacetic acid
4,8-dihydroxyquinoline-2-carboxylic	0	0	54	0
acid
4,5-dihydroxy-1,3-benzenedisulfonic	0	0	54	0	Rose color
acid
Thiosalicylic acid	0	0	54	0	Light yellow
Salicylic acid	0.26	21	18	3.4	Light yellow
2-mercaptonicotinic	0	0	54	0
2-carboxyethylphosphonic acid	0.2	16	19	4.7
cystine	0	0	52	1.1
4,7-dihydroxy-1,10-phenanthroline	0.01	0.8	51	1.1	Redish color
1,4,8,11-tetraazacyclotetradecane-	0.06	4.9	42	3.2
5,7-dione
Fluorexon or {bis[N,N-bis(carboxy-	0.01	0.8	54	0	color
methyl)-aminomethyl]fluorescein}
1997 stabilized 55% HA	0.34	28	16	2.2
“no candidate”
CDTA	0	0	55	0
N,N′-bis(2-carboxyethyl)-	0	0	55	0
N,N′-ethylenediglycine trihydrate
Inositolhexaphosphoric acid	0.12	10	28	5
2,3-dihydroxybenzoic acid	0.02	1.6	50	1.6	Some loss of
					sample before
					titation

Gas Evolution Method

[0014] General Procedure: 4 mL glass vial on Top Loading Balance, 2 mL of Fe(III) [356 mg Fe(III) Sulfate-Hydrate/10 mL H2O {circumflex over (=)}5000 ppm Fe(III)] add to 10 mL plastic beaker with micro stirrer, 100 mL of water or new stabilizer usually at 10000 ppm, 1 mL of either stabilized oder destabilized HA (1997 56%) contents transferred to glass vial+wt loss monitored vs. Time

			1997 destabilized
			2,6-Pyridinedicarboxylic	1997 stabilized
min.	1997	destabilized	acid	H2O
0	6.07	wt loss	0	6.02		0	6.01
1	6.06		5	6.01	.01	3	6.03	0.01
2	6.06	.01	10	5.99	.03	5	5.98	0.06
5	5.98	.09	12	5.99	.03	6	5.90	0.14
7	5.93	.14	14	5.97	.05	10	5.77	0.27
11	5.91	.16	17	5.57	.05	11	5.77	0.27
18	5.90	.17	18	5.96	.06	12	5.76	0.28
21	5.89	.18	23	5.95	.07	13	5.77	0.27
24	5.89	.18	29	5.94	.08	14	5.76	0.28
30	5.88	.19	33	5.93	.09	20	5.76	0.28
36	5.88	.19	43	5.91	0.11	26	5.75	0.29
40	5.88	.19	54	5.91	0.11	30	5.25	0.29
51	5.87	0.20				42	5.74	0.30
61	5.86	0.21
Destabilization procedure - Pass 200 mL of 1997 56% HA through large anion column, collect effluent/Fraction every 50 mL.

Gas Evolution

[0015]

2 mL	5000 ppm	U4A15	U4A13	U4A9	1997 SW	U4AW
	Fe(III)	1.63	mg	1.98	mg	2.21	mg	2.02	1.5
100 mL	H2O	99.18	mg	99.9		100.2	mg	99.9	99.2
	or	10,000	ppm					water
	Stabilizer
1 mL	HA	1189.9	mg	1170	mg	1173	mg	1199	1182
Vial		4.90	g	4.85		4.85		4.88	4.81
											6.02
	1	6.04		1	5.86		1	5.95	0	1	6.02		1	5.97	0
	2	6.04		2	5.82	0	2	5.95	0	2	6.02	0	2	5.97	0
	3	6.03	0.01	3	5.87	−0.01	3	5.95	0	3	6.00	0.02	3	5.96	0.01
	4	6.02	0.02	4	5.87	−0.01	4	5.95	0	4	5.95	0.07	4	5.95	0.02
	5	5.99	0.05	5	5.87	−0.01	5	5.95	0	5	5.86	0.16	5	5.92	0.05
	6	5.95	0.01	6	5.87	−0.01	6	5.95	0	6	5.79	0.03	6	5.89	0.05
	7	5.93	0.11	7	5.87	−0.01	7	5.95	0	7	5.78	0.24	7	5.85	0.12
	8	5.91	0.13	8	5.87	−0.01	8	5.95	0	8	5.77	0.25	8	5.82	0.15
	9	5.91	0.13	9	5.87	−0.01	9	5.95	0	9	5.76	0.26	9	5.82	0.15
	10	5.90	0.14	10	5.86	0	10	5.95	0	10			10	5.81	0.16
	11	5.90	0.14	11	5.86	0	12	5.95	0	11	5.75	0.27	11	5.81	0.16
	15	5.88	0.16	15	5.87	−0.01	15	5.95	0				15	5.80	0.17
	29	5.87	0.17	29	5.87	−0.01	29	5.94	0.01	35	5.73	0.29	31	5.78	0.19
	U4A15 = U destabilized 1997 56%, 4 Fraction #4 150-200 mL, A = 1st destabilized, 15 = 1,4,10,13 tetroxa-7,16-diazabyclooctadecene 104.3 mg/10 mL 29,580-9
	U4A13 = U destabilized, ect, ect, 13 = 4,5-dihydroxy-1,3 benzene disulfonic acid, disodiumsalt 106.3 mg/10 mL 12,255-3
	U4A9 = U destabilized, 9 = 1,4,8,11 Tetraazacyclotetra-decane-1,4,8,11-tetraacetic acid 100.9 mg/10 mL H2O 40,040 mg
	1997SW = stabilized, water
	U4AW = destabilized, Fraction 4, A, water

Gas Evolution

[0016]

		Aldrich
	1997SW	50% HA	U4AW	U4A16	U4A22
2 mL Fe(III)	1.97	mg	2.02		1.89	mg	2.16	mg	1.87	mg
5000 ppm
100 mL water	102.4	mg	101.2	mg	101.6	mg	100.5	mg	99.5	mg
or new stabilizer	H2O	H2O	H2O	16		22
1 mL HA	1221		1209.7		1195	mg	1200		1194
Vial	4.88	g	4.84	g	4.85		4.82		4.92
	0	6.06		0	5.99		0	5.98		0	5.94		0	6.09
	1	6.05	0.01	1	5.99	0	1	5.98	0	1	5.94	0	1	6.09	0
	2	6.04	0.02	2	5.99	0	2	5.98	0	2	5.94	0	2	6.09	0
	3	6.04	0.02	3	5.99	0	3	5.96	0.02	3	5.94	0	3	6.09	0
	4	6.02	0.04	4	5.98	0.01	4	5.95	0.03	4	5.94	0	4	6.08	.01
	5	5.98	0.08	5	5.98	0.01	5	5.91	9.07	5	5.94	0	5	6.07	.02
	6	5.88	0.18	6	5.98	0.01	6	5.87	0.11	6	5.94	0	6	6.07	.02
	7	5.82	0.24	7	5.97	0.02	7	5.86	0.12	7	5.94	0	7	6.07	.02
	8	5.29	0.27	8	5.95	0.04	8	5.85	0.13	8	5.94	0	8	6.06	.03
	9			9	5.95	0.04	9	5.84	0.14	9	5.94	0	9	6.06	.03
	10	5.78	0.28	10	5.94	0.05	10	5.84	0.14	10	5.94	0	10	6.06	.03
				14	5.88	0.11
				15	5.87	0.12	16	5.83	0.16	15	5.94	0	15	6.06	0.04
	20	5.76	0.30	20	5.83	0.16	20	5.81	0.15	20	5.94	0	20	6.03	0.05
	1997SW = 1997 stabilized + H2O
	Aldrich = Aldrich + H2O
	U4AW = 1997 destabilized Fraction 4, A = 1st, water
	U4A16 = Ethylenebis (oxyethylenenitrilo)tetraacetic 99.4 mg/10 mL H2O 40991-0250
	U4A22 = 1,4,8,11-Tetraazacyclotetradecane-5,7-dione 102 mg/10 mL 33,316-6

Gas Evolution Testing of New Stabilizers

[0017]

	1997SW	1997S28	1997S29	1997S14	1997S23	1997S4
2 mL Fe(II)	1.61	mg	1.76	mg	1.84	mg	1.92	1.97	2.00
5000 ppm Fe
100 mL water	100.5	mg	100	mg	101.6	mg	97.2	101.9	96.3
or New			28					23	4
Stabilizer
1 mL HA	1225		1220	mg	1221	mg	1221	1230	1222
Vial	4.85		4.81		4.87		4.85	4.91	4.85
Time	0	6.06			5.98			6.06			6.06		0	6.14	0	6.07
min	1	6.06	0		5.98			6.06			6.06	0	1	6.14	0	6.06	.01
	2	6.05		.01	5.97	.01		6.05	.01		6.07	−.01	2	6.14	0	6.06	.01
	3	6.04		.02	5.96	.02	B	6.05	.01	B	6.06	0	3	6.14	0	6.06	.01
	4	6.04		.02	5.95	.03	B	6.03	.03		6.06	0	4	6.14	0	6.06	.01
	5	6.00		.06	5.89	.09	VB	6.00	.06	VB	6.06	0	5	6.14	0	6.06	.01
	6	5.91		.15	5.83	.15	VB	5.96	.10	VB	6.04	.02	6	6.14	0	6.06	.01
	7	5.81		.25	5.79	.19	B	5.94	.12	VB	6.04	.02	7	6.14	0	6.06	.01
	8	5.75		.31	5.77	.21	B	5.12	.14	B	6.03	.03	8	6.14	0	6.06	.01
	9	5.25		.31	5.76	.22		5.90	.16		6.01	.05	9	6.14	0	6.06	.01
	10	5.75		.31				5.89	.17		6.00	.06	10	6.14	0	6.06	.01
	15	5.73		.33	5.75	.23		5.86	.20	11	5.93	.13	15	6.14	0	6.06	.01
	20	5.72		.34	5.75	.23		5.85	.21	12	5.89	.17	20	6.14	0	6.06	.01
										13	5.82	.24
wt loss	0.34	g	0.23	g	0.21	g	14	5.78	.29	wt loss = 0	wt loss = 0.01
	15	5.77	.29
1997SW = 1997 Stabilized + 100 mL H2O
1997S28 = 1997 Stabilized + 100 mL Polystyrene sulfononic acid-comaleicacid sodiumsalt	102.5 mg/10 mL
1997S29 = 1997 Stabilized + 100 mL Polyacrylic acid sodium salt 40%	304.8 mg/10 mL
1997S14 = 1997 Stabilized + 100 mL 2,5-dihydroxy-1,4-benzenediaceticacid	107.4 mg/10 mL
1997S23* = 1997 Stabilized + 100 mL CDTA	105 mg/10 ml H2O
1997S4* = 1997 Stabilized + 100 mL FLUOREXON	101.3 mg/10 ml H2O
*little or no wt loss: little or no decomposition
B = Bubbles
V = Vigorous

Gas Evolution

[0018]

	U4A17	U4A21	U4A19	U4A23	1997S23
2 mL Fe(III)	1.86	mg	1.90	1.90	1.25		1.80
5000 ppm Fe13
100 mL H2O	100.9	mg	101.3	100.6	11.8	23	11.4	mg	23
or	17		21	19	98.8	H2O	99.9	mg	H2O
New Stabilizer
1 mL HA	1191	mg	1194	1191	1189		1224
Vial	4.96		4.93	4.85	4.84		4.85
	0	6.08		0	6.10		0	6.01		0	6.01		0	6.05
	1	6.07	0.01	1	6.10	0	1	6.01	0	1	6.01	0	1	6.05	0
	2	6.08	0	2	6.10	0	2	6.01	0	2	6.01	0	2	6.05	0
	3	6.06	0.02	3	6.09	0.01	3	6.01	0	3	6.01	0	3	6.05	0
	4	6.04	0.04	4	6.08	0.02	4	6.01	0	4	6.01	0	4	6.05	0
	5	6.02	0.06	5	6.05	0.05	5	6.01	0	5	6.01	0	5	6.05	0
	6	6.00	0.08	6	6.01	0.09	6	6.01	0	6	6.01	0	6	6.05	0
	7	5.99	0.09	7	5.98	0.12	7	6.01	0	7	6.01	0	7	6.05	0
	8	5.97	0.11	8	5.97	0.13	8	6.01	0	8	6.01	0	8	6.05	0
	9	5.96	0.12	9	5.96	0.14	9	6.01	0	9	6.01	0	9	6.05	0
	10	5.95	0.13	10	5.95	0.15	10	6.01	0	10	6.01	0	10	6.05	0
	15	5.94	0.14	15	5.94	0.16	15	6.01	0	15	6.01	0	15
	20	5.93	0.15	20	5.93	0.17	20	6.01	0	20			20	6.05	0
U4A17 U = unstabilized 1997, 4th Fraction,	99 mg/10 mL H2O
A 1st, 17 N,N′ dicarbocymethyl-
diaza-28-crown-6
U4A21 = Krypto Fix 222	106.4 mg/10 mL H2O
U4A19 = Diethylenetriaminepentaacetic	101.4 mg/10 mL
acid 28,556-0
UA23 = CDTA	105 mg/10 ml H2O

[0019]

	1997SW	U4AW	U4A26	U4A25	U4A24	U4A11	U4A14
2 mL Fe(III)	1.94		1.89	1.97	1.99	1.99	1.79	1.88
5000 ppm Fe13
100 mL H2O	100.6	mg	99.8	99.7	101	95.5	99.1	98.9	mg
or				26		25	11	14
New Stabilizer
1 mL HA	1221	mg	1195	1188	1203	Green/	1207
						Yellow	Amber
Vial	4.84		4.84		4.95		4.95		4.87		4.84		4.93
0	6.04		5.99		6.11		6.07		6.02		6.00	0	6.07
1	6.04		5.99	0	6.11	0	6.07		6.02	0	6.00	0	6.07
2	6.04		5.99	0	6.12	−.01	6.07		6.02	0	6.00	0	6.07
3	6.03	.01	5.98	.01	6.11	0	6.07		6.02	0	6.00	0	6.06	.01
4	6.02	.02	5.97	.02	6.11	0	6.07		6.02	0	6.00	0	6.06	.01
5	5.97	.02	5.93	.06	6.11	0	6.07		6.02	0	6.00	0	6.05	.02
6	5.87	.17	5.91	.08	6.11	0	6.06	.01	6.02	0	5.99	.01	6.05	.02
7	5.80	.24	5.89	.10	6.11	0	6.06	.01	6.02	0	6.00	.01	6.04	.03
8	5.78	.26	5.87	.12	6.11	0	6.06	.01	6.02	0	6.00	0	6.03	.04
9	5.77	.27	5.86	.13	6.12	−.01	6.05	.02	6.02	0	6.00	0	6.02	.05
10	5.76	.28	5.86	.13	6.11	0	6.05	.02	6.02	0	6.00	0	6.01	.06
15	5.75	.29	5.83	.16	6.11	0	6.04	.03	6.02	0	5.99	.01	5.98	.09
20	5.75	.29	5.83	.16	6.12	−.01	6.04	.03	6.02	0	5.99	.01	5.97	.10
1997SW 1997 stabilized water
U4AW 1997 destabilized + water
U4A26* 1997 destabilized + triethylenetetraamine,	105.6 mg/10 mL
N,N,N′,N″,N′″,N′″ hexaacetic acid
U4A25 1997 destabilized + inositole hexa-	187 mg/10 mL
phosphoric acid 40-50%
U4A24* 4,8 dihydroxyguinoline-2-carboxylic	99.6 mg/10 mL
acid
U4A11* 4,7 dihydroxy-1,10-phenanthroline	51.3 mg/10 mL
UA414 2,5 dihydroxy-1,4-benzenediacetic acid	107.4 mg/10 mL

General Titration Procedure

[0020] Determination of remaining NH2OH after gas evolution Test: General Procedure: First wash contents of 10 mL plastic beaker with 2 mL conc HCl+5 mL H2O, transfer HCl+washings to 200 ml Volumetric Flask. After completion of-the gas evolution experiment, transfer contents of 4 mL Vial to 200 mL Volumetric Flask. Add 2 ml HCl to Vial wash with 10-20 mL H2O, Transfer all washings to 200 mL volumetric Flask. Dilute up to Volume. Take 10 mL aliquot and titrate with 0.25 N NaOH. From page 27 calculation for HA=Hydroxylamine 1 mL={circumflex over (=)}1.1 g 1$\mathrm{mL}\times \frac{\mathrm{.25}\mathrm{mole}}{1000\mathrm{mL}}\times \frac{1}{1.1g}\times \frac{33g}{\mathrm{mole}}\times \frac{200\mathrm{mL}}{10\mathrm{mL}}\times 100=\%\mathrm{HA}\mathrm{or}\mathrm{mL}\times 15$

[0021] 1997SW=1 mL 1997 Stabilized+100 ml H2O+2 mL Fe+3 (5000 ppm) 1

[0022] 1997S28=Inl 1997 Stabilized+100 mL Polystyrenesulfonate-co-maleic acid, sodium salt+2 mL (Fe+3 5000 ppm) 2

[0023] 1997S29=1 mL 1997 stabilized+100 ml of {circumflex over (=)}10000 ppm polyacrylic acid sodium salt 40% 304.8 mg/10 mL+2 ml of Fe(III) 5000 ppm 3

[0024] 1997S14=1 mL 1997 stabilized+100 mL of 2,5 dihydroxy-1,4-benzenediacetic aicd 107.4 mg/10 mL, +2 mL of Fe(III) 5000 ppm 4

[0025] 1997S23=1 mL 1997 stabilized+100 mL of CDTA 105 mg/10 mL, 2 mL of Fe(III) 5000 ppm 5

[0026] 1997S4=1 mL 1997 stabilized+100 mL of Fluorexon (11,985-7 Cat# Aldrich 101.3 mg/10 mL+2 mL of Fe(III) 5000 ppm 6

[0027] HA=hydroxyl amine Note 1997S23+19974 showed little or no decomposition

Gas Evolution

[0028]

2 mL Fe(III) 500 ppm	1997S32		1997S31
	1.97	mg		1.93	mg
100 mL H2O or New Stabilizer	101	mg		101.3	mg
1 mL of 1997S Σ	1218	mg		1222	mg
Vial empty	4.93	g		4.89
	0		6.10	0		6.09
	1			1		6.09
	2		6.10	2		6.09 B
	3		6.08 B	3		6.08
	4		6.08 B	4		6.06 VB
	5		6.05 VB	5		6.03 VB
	6		6.02 VB	6		5.93
	7		6.00 VB	7		5.83 VB
	8		5.98	8		5.77 VB
	9		5.97	9		5.75
	10		5.95	10		5.74
	15		5.91	15		5.73
	20		5.89	20		5.72
	wt loss	0.21 g	wt loss	0.37
1997S32 = 1 mL 1997S	1997S31 = 1 mL 1997S
113 mg/10 mL 1,2bis(2 amino phenoxy) ethane	100 ml of Trans-Aconitric acid
N,N,N′,N′ tetracetic acid	105 mg/10 mL

[0029] 7

[0030] B=Bubbles

[0031] V=Vigorous

Gas Evolution+Titration

[0032]

	Sample
	1997S34	1997S35	HA = Hydroxylamine
2 mL Fe(III) 5000 ppm	1.98	mg	1.98	mg	Note 1997S35
100 mL New Stabilizer	101	mg	102.5	mg	little or NO wt loss
1 mL 1997S Σ	1229	mg	Σ 1225	mg	in little or NO HA
Vial empty	4.90	g	4.82	g	decomposition
	Time		Time
	Min		Min
	0	6.12	0	6.05
	1	6.12	1	6.05
	2	6.11	2	6.05
	3	6.10 B	3	6.05
	4	6.09	4	6.05
	5	6.04 VB	5	6.05
	6	5.92	6	6.05
	7	5.84 VB	7	6.05
	8	5.82	8	6.04 B
	9	5.81	9	6.04
	10	5.80	10	6.05
	15	5.79	15	6.04
	20	5.79	20	6.03
	wt loss	0.33 g	wt loss	0.02 g
1 mL 1997S	1 mL 1997S
100 mL 34 = 1,1′-Ethylenebis(5-oxo-3-	100 mL 109 mg
pyrrolidine carboxylic acid Cat# 32, 756-S	2,3 dihydroxybenzoic
Alrich	acid

[0033] 8

Gas Evolution+Titration

[0034]

	sample
	1997S33	1997S19	1997S36	1997S40	1997S26
5000 ppm Fe	2.17	mg	2.43	mg	2.09	mg	2.11	mg	1.98	mg
2 mL
100 mL	101.8	mg	Σ 101.6	mg	100.8	mg	101	mg	100	mg
New Stabilizer Σ
1 mL 1997S Σ	1225	mg	Σ 1224	mg	Σ 1220	mg	1220	mg	1220	mg
Vial empty	4.93	g	4.88	g	4.88	g	4.82	g	4.85	g
Time Minutes
0	6.13	g	6.09	g	6.10	g	5.95	g	6.07	g
1	6.13	g	6.10	g	6.10	g	5.95	g	6.07	g
2	6.13	g	6.10	g	6.10	g	5.95	g	6.07	g
3	6.12	g B	6.10	g	6.10	g	5.94	g	6.07	g
4	6.10	g	6.10	g	6.10	g	5.92	g VB	6.07	g
5	6.03	g VB	6.10	g	6.10	g	5.89	g VB	6.07	g
6	5.93	g VB	6.10	g	6.10	g	5.83	g VB	6.07	g
7	5.88	g VB	6.10	g	6.10	g	5.78	g VB	6.07	g
8	5.86	g	6.10	g	6.10	g	5.75	g	6.07	g
9	5.85	g	6.10	g	6.10	g	5.73	g	6.07	g
10	5.85	g	6.10	g	6.10	g	5.73	g	6.07	g
15	5.84	g	6.09	g	6.10	g	5.71	g	6.07	g
20	5.84	g	6.10	g	6.10	g	5.70	g	6.07	g
	wt 0.29	g	wt 0	g	wt 0	g	wt 0.25	g	wt 0	g
	loos		loss		loss		loss		loss
1997S33 = 1 mL 1997s + 100 mL 2,2′-(Ethylenedithio)diacetic acid 103 mg/10 mL, 2 mL pf 5000 ppm Fe

[0035] 9

[0036] Note 1997S19, 1997S36+1997S26 showed little or no wt loss in or no decomposition

Gas Evolution+Titration

[0037] 1997S19=1 mL 1997 Stabilized, 100 mL of Diethylene triamine pentaacetic acid (28,556-0 cat# Aldrich) 101.4 mg/10 mL, 2 mL of 5000 ppm Fe 10

[0038] 1997S36=1 mL 1997 Stabilized, 100 mL of N,N′-Bis(2-carboxyethyl)-N,N′ethylenediglycine trihydrate (Aldrich 28,584-6) 11

[0039] 1997S40=1 mL 1997 stabilized, 100 mL 1,2,3,4 Butanetetracarboxylic acid 105.9 mg/10 mL, 2 mL of 5000 ppm Fe 12

[0040] 1997S26=1 mL 1997 Stabilized, 100 mL Triethylenetetramine N,N,N,N, hexaacetic acid 13

Gas Evolution+Titration

[0041]

	sample
	1997S9	1997S13	1997S16	1997S22	1997S24	1997S11	1997S25
5000 ppm Fe	1.72 mg	2.07		1.70	2.02		1.89		1.76		2
2 mL
New Stabilizer	Σ 101.4 mg	101.9	Green	101.2	100		99.7	Greenish	98.4	Redish	99
100 mL			Color					Color
1997S H-Base	Σ 1220 mg	1221	Rose	1220	1222		1218	Yellow	1215		1224
55% HA 1 mL			Color
Vial Empty	4.86	4.90		4.83	4.89		4.85		4.95		4.83
Time (Min.)
0	6.05	6.12		6.07	6.10		6.04		6.11		6.07
1	6.05	6.12		6.07	6.10		6.04		6.11		6.07
2	6.05	6.12		6.07	6.09		6.04		6.11		6.07
3	6.05	6.12		6.07	6.08	B	6.04		6.11		6.07
4	6.05	6.12		6.07	6.08		6.04		6.11		6.08
5	6.05	6.12		6.07	6.07		6.04		6.11		6.07
6	6.05	6.12		6.07	6.07		6.04		6.11		6.07
7	6.05	6.12		6.07	6.06		6.04		6.11		6.05
8	6.05	6.12		6.07	6.06		6.04		6.11		6.04
9	6.05	6.12		6.07	6.06		6.04		6.11		6.04
10	6.05	6.12		6.07	6.05		6.04		6.11		6.03
15	6.05	6.12		6.07	6.04		6.04		6.11		5.98
20	6.05	6.12		6.07	6.04		6.04		6.10		5.95
wt loss	0	0		0	.06	mg	0		.01		0.12	g
sample	1997S13	0	6.06
5000 ppm		1	6.06
2 mL Fe	2.00	2	6.06
New		3	6.06
Stabilizer	100.3	4	6.05
1997S		5	6.05
HB	1220	6	5.92
		7	5.82
Vial	4.87	8	5.80
		9	5.79
		10	5.79
		15	5.79
		20	5.79

[0042] 1997S9=1 mL 1997 Stabilized HBase 55% HA, 100 mL of 1,4,8,11 Tetraazacyclotetradecane-1,4,8,11-tetracetic acid (Aldrich 40,040-8) 100.9 mg/10 mL H2O, 2 mL of 5000 ppm Fe(III) 14

[0043] 1997S13=1 mL 1997 Stabilized HB 55% HA, 100 mL of 4,5 Dihydroxy-1,3-benzene disulfonic Acid, disodiumsalt (Aldrich 17,255-3) 106.3 mg/10 mL H2O, 2 mL 5000 ppm Fe(III) 15

[0044] 1997S 16=1 mL 1997 Stabilized HB 55% HA, 100 mL of Ethylene bis(oxyethylenenitriolo)-tetraacetic acie (40991-0250) 99.4 mg/10 mg H2O, 2 mL of 5000 ppm Fe(III) 16

[0045] 1997S22=1 mL 1997 Stabilized HBase 55% HA, 100 mL of 1,4,8,11-tetraazacycloetradecane-5,7-dione (33,316-6 cat#) 102 mg/10 mL, 2 mL of 5000 ppm Fe 17

[0046] 1997S24=1 mL 1997 Stabilized HBase 55% HA, 100 mL of 4,8-Dihydroxy quinoline-2-carboxylic acid 99.6 mg/10 mL, 2 mL of 5000 ppm Fe 18

[0047] 1997S11=1 mL 1997 Stabilized HBase 55% HA, 100 mL of 4,7 dihydroxy 1,10 phenanthroline 51.3 mg/10 mL, 2 mL of 5000 ppm Fe(III) 19

[0048] 1997S25=1 mL 1997 Stabilized HBase 55% HA, 100 mL of Inositol hexaphosphoric acid (40-50% Sol'n) 187 mg/10 mL, 2 mL of 5000 ppm Fe 20

[0049] 1997S15=1 mL 1997 Stabilized HBase 55% HA, 100 mL of 1,4,10,13-tetroxa-7,16-diazacyclooctadecane (29,580-9 Aldrich) 104.3 mg/1 mL H2O, 2 mL of 5000 ppm Fe 21

Gas Evolution+Titration of New Stabilizer

[0050]

	sample
	1997S41	1997S42	1997S39	1997S38	1997S37
5000 ppm	1.94	mg	2.09	mg	1.70	mg		2.07	mg		2.22	mg
Fe 2 mL
New Stabilizer	Σ 1023	mg	97.7	mg	100.4	mg	red	100	mg	Green	100	mg
100 mL
1997S 56%	Σ 1224	mg	1221	mg	1238	mg	light	1224	mg	light	1238	mg
HA 1 mL							yellow			orange
empty Vial	4.85	g	4.87	g	4.95	g		4.82	g		4.88	g
Time (Min.)
0	6.06		6.08		6.17			6.05			6.11
1	6.06		6.08		6.17			6.05			6.11
2	6.06		6.08		6.17			6.05			6.11
3	6.06		6.08		6.16			6.05			6.11
4	6.04		6.08		6.14			6.05			6.11
5	6.03		6.07		6.11			6.05			6.11
6	5.98		6.07		6.05			6.05			6.11
7	5.88		6.07		5.99			6.05			6.11
8	5.82		6.06		5.95			6.05			6.11
9	5.78		6.06		5.94			6.05			6.11
10	5.76		6.06		5.93			6.05			6.11
15	5.75		6.05		5.92			6.05			6.11
20	5.74		6.04		5.91			6.05			6.11
wt loss	0.32	g	0.04	g	0.26	g		0	mg		0	g

[0051] 1997S41=1 mL 1997 Stabilized HBase 56% HA, 100 mL of (±)Cis-Epoxytricarbollylic acid 100 mg/10 mL, 2 mL of 5000 ppm FE(III)

[0052] vial+¾ mL HCl→200 mL, 10 mL aliquot 22

[0053] 1997S42=1 mL 1997 Stabilized HBase 56% HA, 100 mL of N-(2-Acetamidaminodiacetic acid 105 mg/10 mL, 2 ml of 5000 ppm Fe(III) 2$\begin{array}{cc}\mathrm{HCL}& 5.209\\ +& \\ {\mathrm{NH}}_3\mathrm{OH}& 8.160\\ +& \\ {\mathrm{NH}}_4& 8.563\end{array}\begin{array}{c}\\ 2.951\mathrm{mL}\times 15\\ \\ 0.403\mathrm{mL}\times 7.7\\ \end{array}\begin{array}{c}\\ 44.3\%\mathrm{HA}{\mathrm{NH}}_2\mathrm{OH}\\ \\ 3.1\%{\mathrm{NH}}_3\\ \end{array}$

[0054] 1997S39=1 mL 1997S Stabilized 56% HA, 100 mL of Salicylic Acid 7.8 mg/10 mL, 2 mL of Fe(III) 5000 ppm 23

[0055] 1997S38=1 mL 1997S Stabilized 56% HA, 100 mL of Thiosalicylic acid 101.6 mg/1 mL, 2 mL of 5000 ppm Fe(III) 24

[0056] 1997S37=1 mL 1997S Stabilized 56% HA, 100 mL of CDTA 112 mg/10 mL, 2 mL of 5000 ppm Fe(III) 25

New Stabilizer Screening

Gas Evolution+Titration

[0057]

	sample
	1997S43	1997S45	1007S46
2 mL 500 ppm Fe(III)		1.80	mg	100	mg	1.93
new stabilizer 100 mL		100	mg	100	mg	100.7
1997S H-base 56%		1223	mg	1229	mg	1232
Hydroxylamine
Vial	min	4.83	g	4.91	g	4.92	g
	0	6.06		6.11		6.15
	1	6.06		6.11		6.15
Note: After wt loss content	2	6.06		6.12		6.15
of vial transferred to 200 mL	3	6.05		6.12		6.15
Volumetric Flask, 3-4 mL	4	6.04		6.12		6.15
	5	6.02		6.12		6.15
Conc HCl Aldrich, diluted	6	6.00		6.12		6.15
	7	5.98		6.12		6.15
to volume, 10 mL aliquot	8	5.95		6.12		6.15
titrated using 0.25 NaOH	9	5.93		6.12		6.15
	10	5.91		6.12		6.15
	15	5.88		6.12		6.15
	20	5.86		6.12		6.15
wt loss		0.20	g	0	g	0	g

[0058] 1997S43=1 mL 1997S 56% HA, 100 mL of 2-Carboyethylphosphonic acid, 2 mL of 5000 ppm Fe(III) 3$\begin{array}{cc}\mathrm{HCl}& 3.660\mathrm{mL}\\ +& \\ {\mathrm{NH}}_3\mathrm{OH}& 4.914\mathrm{mL}\\ +& \\ {\mathrm{NH}}_4& 5.526\mathrm{mL}\end{array}\begin{array}{c}\\ 1.254\mathrm{mL}\times 15=18.8\%\mathrm{HA}\\ \\ 0.612\mathrm{mL}\times 7.7=4.7\%{\mathrm{NH}}_3\\ \end{array}$

[0059] 1997S45=1 mL 1997S 56% HA, 100 mL of Mercaptonicotinic Acid 97.9 mg/10 mL, 2 mL of 5000 ppm Fe(III) 4$\begin{array}{cc}\mathrm{HCl}& 2.704\\ +& \\ {\mathrm{NH}}_3\mathrm{OH}& 6.314\\ +& \\ {\mathrm{NH}}_4& 0\end{array}3.61\mathrm{mL}\times 15=54\%\mathrm{HA}$

[0060] 1997S46=1 mL 1997S 56% HA, 100 mL of cyxtine 96 mg/10 mL 2 mL of 5000 ppm Fe(III) 5$\begin{array}{cc}\mathrm{HCl}& 2.767\\ +& \\ {\mathrm{NH}}_3\mathrm{OH}& 6.232=3.465\times 15\\ +& \\ {\mathrm{NH}}_4& 6.379=0.147\times 7.7\end{array}\begin{array}{c}\\ \\ 52\%\mathrm{HA}\\ \\ 1.1\%{\mathrm{NH}}_3\end{array}\begin{array}{c}\\ \end{array}$

Claims

1. A stabilized hydroxylamine solution comprising a selected stabilizer selected from the group consisting of (a) diethylenetriaminepentaacetic acid (b) triethylenetetraminehexaacetic acid (c) ethylenebis(oxyethylenenitrilo)-tetraacetic acid, (d) 1,4,8,11-tetraazacyclotetradecane-1,4,8-11-tetraacetic acid, (e) 4,8-dihydroxyquinoline-2-carboxylic acid, (f) 4,5-dihydroxy-1,3-benzenedisulfonic acid, (g) 4,7-dihydroxy-1,10-phenanthroline, (h) 2-mercapto-nicotinic acid 1,4,8,11-tetraazacyclotetradecane-5,7-dione, (i) bis[N,N-bis(carboxymethyl)-aminomethyl]fluorescein, (j) N,N′-bis(2-carboxyethyl)-N,N′ethylenediglycine trihydrate, (k) cystine, (1) 2,3-dihydroxybenzoic acid, (m) thiosalicylic acid and any mixture of the foregoing.

2. The stabilized solution as defined in claim 1 wherein said stabilizer is present in said solution in an amount ranging from about 0.005 percent to about 0.1 percent by weight to the total weight of the stabilized solution.

3. A method of stabilizing a hydroxylamine solution which comprises adding at least one selected stabilizer to the solution.

4. The method as defined in claim 1 wherein said stabilizer is selected from the group consisting of (a) diethylenetriaminepentaacetic acid, (b) triethylenetetraminehexaacetic acid, (c) ethylenebis(oxyethylenenitrilo)tetraacetic acid (“EGTA”), (d) 1,4,8,11-tetraazacyclotetradecane-1,4,8-11-tetraacetic acid, (e) 4,8-dihydroxyquinoline-2-carboxylic acid, (f) 4,5-dihydroxy-1,3-benzenedisulfonic acid, (g) 4,7-dihydroxy-1,10-phenanthroline, (h) 2-mercaptonicotinic acid, (i) bis[N,N-bis(carboxymethyl)-aminomethyl]fluorescein, (j) N,N-bis(2-carboxyethyl)-N,N′ethylenediglycine trihydrate, (k) cystine, (1) 2,3-dihydroxybenzoic acid, (m) thiosalicylic acid and any mixture of the foregoing.

5. The method as defined in claim 4 wherein said stabilizer is added to yield an amount thereof in the solution of about 0.005 percent to about 0.1 percent by weight to the total weight of the solution.